# EDGAR Filing Document

**Accession Number:** 0002004489
**File Stem:** 0001493152-26-003001
**Filing Date:** 2026-1
**Character Count:** 3242
**Document Hash:** 03c437449181bda428ffb20134ca5b1a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-003001.hdr.sgml**: 20260121

**ACCESSION NUMBER**: 0001493152-26-003001

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260121

**FILED AS OF DATE**: 20260121

**DATE AS OF CHANGE**: 20260121

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Basel Medical Group Ltd
- **CENTRAL INDEX KEY:** 0002004489
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE [8011]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** D8
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42527
- **FILM NUMBER:** 26544856

**BUSINESS ADDRESS:**
- **STREET 1:** 600 NORTH BRIDGE ROAD, #12-02/03
- **STREET 2:** PARKVIEW SQUARE
- **CITY:** SINGAPORE
- **STATE:** U0
- **ZIP:** 188778
- **BUSINESS PHONE:** 65 6291 9188

**MAIL ADDRESS:**
- **STREET 1:** 600 NORTH BRIDGE ROAD, #12-02/03
- **STREET 2:** PARKVIEW SQUARE
- **CITY:** SINGAPORE
- **STATE:** U0
- **ZIP:** 188778

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of January 2026**

**Commission File Number: 001-42527**

**Basel Medical Group Ltd**

**6 Napier Road, Unit #02-10/11 Gleneagles Medical Centre**

**Singapore 258499**

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

**Explanatory Note**

On April 11, 2025, Basel Medical Group Pte. Ltd. ("BMGPL"), a subsidiary of Basel Medical Group Ltd (Nasdaq: BMGL), entered into a sale and purchase agreement (the "Sale and Purchase Agreement") with Silkroute Biomed Healthcare Pte. Ltd. (the "Seller") for the acquisition of all of the ordinary shares in the issued and paid-up share capital (the "Sale Shares") of Bethesda Medical Pte. Ltd., a company incorporated in Singapore ("Bethesda Medical"). The acquisition of Bethesda Medical pursuant to the Sale and Purchase Agreement was completed on April 30, 2025. Following such completion, Bethesda Medical became a wholly owned indirect subsidiary of Basel Medical Group Ltd. Upon completion, BMGPL paid the Seller a sum of US$6.5 million for such acquisition, and subsequently BMGPL and the Seller further agreed that the remaining deferred consideration of US$1.5 million shall be waived. Following such agreement, the total consideration of US$6.5 million for the acquisition of Bethesda Medical has been fully satisfied by BMGPL.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Basel Medical Group Ltd** | **Basel Medical Group Ltd** |
|  | By: | */s/ Darren Yen Feng Chhoa* |
|  | Name: | Dr. Darren Yen Feng Chhoa |
|  | Title: | Chief Executive Officer |
| Date: January 21, 2026 |  |  |

---